Company overview
Basic information
Company name
Sveikata iš gamtos, MB
Company code
306127616
VAT code
LT100015210711
Registered address
Kauno r. sav., Domeikavos sen., Žemaitkiemio k., Žalčio g. 20, LT-54340
Registration date
2022-08-05
Company age: 4 y. 1 mo.
Contact information
Edit data
Phone
Email
Presented as an image – cannot be copied
Website
https://www.sveikataisgamtos.lt
Company manager
For registered members only
Log in
Indicators
Risk factors
Activity
Legal form
Small partnership
NACE activity
Retail sale of pharmaceutical products
Ownership form
Private without foreign capital
MB Sveikata iš gamtos
Company code: 306127616
Address: Kauno r. sav., Domeikavos sen., Žemaitkiemio k., Žalčio g. 20, LT-54340
VAT code: LT100015210711
Download a detailed company report
Make confident decisions with all the information about Sveikata iš gamtos, MB. In one document, you will find full financial data, risk and potential assessment, and key Scoris insights.
Description
This description was generated by artificial intelligence.
Sveikata iš gamtos, MB (company code 306127616) is an operational private small partnership registered on 2022-08-05. It is part of the national private non-financial companies sector and is privately owned, meaning Lithuanian natural and legal persons hold more than 50% of the authorised capital and there is no foreign investor capital. Governance is listed as CEO only. The company is based at Žalcio g. 20, Žemaitkiemio k., Domeikavos sen., Kauno r. sav., Kauno apskr., Lithuania.
Its registered activity is EVRK G.47.73.00, Retail sale of pharmaceutical products. Financially, the company increased revenue from €66.2K in 2023 to €72.6K in 2024 and €87.2K in 2025. Net profit rose from €2.5K in 2023 to €3.4K in 2024 and €6.0K in 2025, while the profit margin improved from 3.7% to 4.7% and then 6.9%. Total assets grew from €10.3K in 2023 to €13.1K in 2024 and €22.7K in 2025. Equity increased to €12.4K in 2025, with liabilities at €10.3K.
Its registered activity is EVRK G.47.73.00, Retail sale of pharmaceutical products. Financially, the company increased revenue from €66.2K in 2023 to €72.6K in 2024 and €87.2K in 2025. Net profit rose from €2.5K in 2023 to €3.4K in 2024 and €6.0K in 2025, while the profit margin improved from 3.7% to 4.7% and then 6.9%. Total assets grew from €10.3K in 2023 to €13.1K in 2024 and €22.7K in 2025. Equity increased to €12.4K in 2025, with liabilities at €10.3K.